[ 18F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [ 18F]FDOPA and [ 11C]DASB PET study in Parkinson's disease

NeuroImage

Volumn 59, Issue 2, 2012, Pages 1080-1084

  Pavese, N ^a   Simpson, B S ^a   Metta, V ^b   Ramlackhansingh, A ^a   Chaudhuri, K Ray ^b   Brooks, D J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

11C DASB serotonin Parkinson; 18F FDOPA; Extrastriatal; Monoamine; Positron emission tomography (PET)

Indexed keywords

6 FLUORODOPA F 18; CARBON 11; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; 3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLSULFANYL)BENZONITRILE; 3-AMINO-4-(2-DIMETHYLAMINOMETHYLPHENYLSULFANYL)BENZONITRILE; ANILINE DERIVATIVE; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; SULFIDE;

AGED; ANTERIOR CINGULATE; ARTICLE; BRAIN REGION; BRAIN STEM; CLINICAL ARTICLE; DOPAMINERGIC NERVE CELL; DRUG BINDING; DRUG TRANSPORT; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPOTHALAMUS; MALE; MEASUREMENT; NERVOUS SYSTEM FUNCTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAPHE NUCLEUS; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; BIOAVAILABILITY; METABOLISM; METHODOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

AGED; ANILINE COMPOUNDS; BIOLOGICAL AVAILABILITY; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; MALE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RAPHE NUCLEI; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SULFIDES; TISSUE DISTRIBUTION;

EID: 83055181125     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.09.034     Document Type: Article

References (33)

1. Azmitia E.C., Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol. 1978, 179:641-668.
2. Baker K.G., Halliday G.M., Hornung J.P., Geffen L.B., Cotton R.G., Törk I. Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. Neuroscience 1991, 42:757-775.
3. Bogdanski, D.f., Weissbach H., Udenfriend S. The distribution of serotonin, 5-hydroxytryptophan decarboxylase, and monoamine oxidase in brain. J. Neurochem. 1957, 1:272-278.
4. Brown W.D., Taylor M.D., Roberts A.D., Oakes T.R., Schueller M.J., Holden J.E., Malischke L.M., DeJesus O.T., Nickles R.J. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 1999, 53:1212-1218.
5. Cumming P., Ljubic-Thibal V., Laliberté C., Diksic M. The effect of unilateral neurotoxic lesions to serotonin fibres in the medial forebrain bundle on the metabolism of [3H]DOPA in the telencephalon of the living rat. Brain Res. 1997, 747:60-69.
6. Dahlström A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in cell bodies of brainstem neurons. Acta Physiol. Scand. Suppl. 1964, 232:1-55.
7. Gerfen C.R. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J. Neurosci. 1987, 7:3915-3934.
8. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997, 6:279-287.
9. Houle S., Ginovart N., Hussey D., Meyer J.H., Wilson A.A. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur. J. Nucl. Med. 2000, 27:1719-1722.
10. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
11. Jaeger C.B., Ruggiero D.A., Albert V.A., Joh T.H., Reis D.J. Immunochytochemical localization of aromatic-L-aminoacid decarboxylase. Handbook of chemical neuroanatomy 1984, vol. 2:387-408. Elsevier, Amsterdam. A. Björklund, T. Hökfelt (Eds.).
12. Kaasinen V., Nurmi E., Brück A., Eskola O., Bergman J., Solin O., Rinne J.O. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 2001, 124:1125-1130.
13. Kasper S., Tauscher J., Willeit M., Stamenkovic M., Neumeister A., Küfferle B., Barnas C., Stastny J., Praschak-Rieder N., Pezawas L., de Zwaan M., Quiner S., Pirker W., Asenbaum S., Podreka I., Brücke T. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J. Biol. Psychiatry 2002, 3:133-146.
14. Kim S.E., Choi J.Y., Choe Y.S., Choi Y., Lee W.Y. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J. Nucl. Med. 2003, 44:870-876.
15. Kim J.S., Ichise M., Sangare J., Inni R.B. PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. J. Nucl. Med. 2006, 47:208-214.
16. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
17. Kumakura Y., Danielsen E.H., Gjedde A., Vernaleken I., Buchholz H.G., Heinz A., Gründer G., Bartenstein P., Cumming P. Elevated [(18)F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease. Neuroimage 2010, 49:2933-2939.
18. Lindvall O., Björklund A. Anatomy of the dopaminergic neuron systems in the rat brain. Adv. Biochem. Psychopharmacol. 1978, 19:1-23.
19. Mantere T., Tupala E., Hall H., Särkioja T., Räsänen P., Bergström K., Callaway J., Tiihonen J. Serotonin transporter distribution and density in the cerebral cortex of alcoholic and nonalcoholic comparison subjects: a whole-hemisphere autoradiography study. Am. J. Psychiatry 2002, 159:599-606.
20. Moore R.Y., Whone A.L., McGowan S., Brooks D.J. Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Res. 2003, 982:137-145.
21. Moore R.Y., Whone A.L., Brooks D.J. Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol. Dis. 2008, 29:381-390.
22. Murai T., Müller U., Werheid K., Sorger D., Reuter M., Becker T., von Cramon D.Y., Barthel H. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 2001, 13:222-228.
23. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., Ruth T.J., Calne D.B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 1993, 34:331-338.
24. Pavese N., Moore R.Y., Scherfler C., Khan N.L., Hotton G., Quinn N.P., Bhatia K.P., Wood N.W., Brooks D.J., Lees A.J., Piccini P. In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp. Neurol. 2010, 222:120-124.
25. Pavese N., Rivero-Bosch M., Lewis S.J., Whone A.L., Brooks D.J. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal (18)F-dopa PET study. Neuroimage 2011, 56:1463-1468.
26. Pirker W., Asenbaum S., Hauk M., Kandlhofer S., Tauscher J., Willeit M., Neumeister A., Praschak-Rieder N., Angelberger P., Brücke T. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J. Nucl. Med. 2000, 41:36-44.
27. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D.J., Piccini P. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 2010, 40:216-221.
28. Rakshi J.S., Uema T., Ito K., Bailey D.L., Morrish P.K., Ashburner J., Dagher A., Jenkins I.H., Friston K.J., Brooks D.J. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [18F]Dopa-PET study. Brain 1999, 122:1637-1650.
29. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., Kimura H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 1993, 34:324-330.
30. Steinbusch H.W. Serotonin-immunoreactive neurons and their projections in the CNS. Handbook of chemical neuroanatomy 1984, vol. 3:68-125. Elsevier, Amsterdam. A. Björklund, T. Hökfelt, M.J. Kuhar (Eds.).
31. Takano H., Ito H., Takahashi H., Arakawa R., Okumura M., Kodaka F., Otsuka T., Kato M., Suhara T. Serotonergic neurotransmission in the living human brain: A positron emission tomography study using [(11)C]dasb and [(11)C]WAY100635 in young healthy men. Synapse 2010, Epub 23rd November PMID: 21108240.
32. van de Kar L.D., Lorens S.A. Differential serotonergic innervation of individual hypothalamic nuclei and other forebrain regions by the dorsal and median midbrain raphe nuclei. Brain Res. 1979, 162:45-54.
33. Whone A.L., Moore R.Y., Piccini P., Brooks D.J. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann. Neurol. 2003, 53:206-216.